a Hospices Civils de Lyon, Hematology Department , Lyon-Sud Hospital , Pierre Bénite , France.
Expert Opin Biol Ther. 2018 Nov;18(11):1095-1106. doi: 10.1080/14712598.2018.1533951. Epub 2018 Oct 12.
Cellular immunotherapy with autologous or allogeneic T cells, genetically engineered to express chimeric antigen receptors (CARs) or T-cell receptors, in order to redirect their cytotoxic specificity toward malignant cells, is emerging as a promising new treatment modality. The most advanced approach in clinical development is the use of anti-CD19 CAR T-cells for the treatment of CD19 B-cell malignancies, including acute lymphocytic leukemia (ALL). Areas covered: Recently, the Food and Drug Administration (FDA) approved the first anti-CD19 CAR T-cell product, tisagenlecleucel, for the treatment of pediatric and young adult patients with relapsed/refractory ALL. In this overview, we described the advances in the field, including a summary of clinical trials with tisagenlecleucel in ALL published to date. Expert opinion: CAR T-cell therapy has been developed in the context of small clinical studies and very few centers have had to deal with the challenges of managing CAR T-cells administration. However, this approach is likely to become a standard option for patients with relapsed/refractory B-cell lineage ALL.
嵌合抗原受体 (CAR) 或 T 细胞受体基因修饰的自体或同种异体 T 细胞的细胞免疫疗法，旨在将其细胞毒性特异性重新导向恶性细胞，正在成为一种有前途的新治疗方式。在临床开发中最先进的方法是使用抗 CD19 CAR T 细胞治疗 CD19 B 细胞恶性肿瘤，包括急性淋巴细胞白血病 (ALL)。
最近，美国食品和药物管理局 (FDA) 批准了首个抗 CD19 CAR T 细胞产品 tisagenlecleucel，用于治疗复发性/难治性 ALL 的儿科和年轻成年患者。在这篇综述中，我们描述了该领域的进展，包括迄今为止发表的 tisagenlecleucel 在 ALL 中临床试验的总结。
CAR T 细胞疗法是在小型临床研究的背景下开发的，只有极少数中心不得不应对管理 CAR T 细胞给药的挑战。然而，这种方法很可能成为复发性/难治性 B 细胞系 ALL 患者的标准选择。
